Theragnostic liposomes for the diagnosis and treatment of tuberculosis

Rebeca Jiménez-Rodríguez; Janna Douda; I. I. Mota-Díaz; Julieta Luna-Herrera; I. C. Romera-Ibarra; J. L. Casas-Espínola

doi:10.1557/s43580-023-00496-3

Theragnostic liposomes for the diagnosis and treatment of tuberculosis

Rebeca Jiménez-Rodríguez, Janna Douda, I. I. Mota-Díaz, Julieta Luna-Herrera, I. C. Romera-Ibarra, J. L. Casas-Espínola

Producción científica: Contribución a una revista › Artículo › revisión exhaustiva

2 Citas (Scopus)

Resumen

The indiscriminate use of antibiotics has generated super bacteria resistant to many conventional drugs. Tuberculosis is caused by the bacterium Mycobacterium tuberculosis, the use of conventional treatments for this disease generates significant damage to the liver and kidney functions of patients, which is why treatments are required that allow early diagnosis and selectivity for Pathogenic bacteria. In this work, a drug currently used for the treatment of tuberculosis (rifampicin) and silver nanoparticles as luminescent biomarkers are being encapsulated, and estimated by means of UV–VIS, FTIR, and DLS techniques for the design of theragnostic liposomes. The results show that this type of liposomes have important characteristics to be used as elements of early diagnosis in addition to its possible therapeutic use. Graphical abstract: [Figure not available: see fulltext.]

Idioma original	Inglés
Páginas (desde-hasta)	67-70
Número de páginas	4
Publicación	MRS Advances
Volumen	8
N.º	3
DOI	https://doi.org/10.1557/s43580-023-00496-3
Estado	Publicada - abr. 2023

ODS de las Naciones Unidas

Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

Acceder al documento

10.1557/s43580-023-00496-3

Otros archivos y enlaces

Enlace a la publicación en Scopus

Citar esto

@article{7376d7944a2e4b078357c6837d2aa0da,

title = "Theragnostic liposomes for the diagnosis and treatment of tuberculosis",

abstract = "The indiscriminate use of antibiotics has generated super bacteria resistant to many conventional drugs. Tuberculosis is caused by the bacterium Mycobacterium tuberculosis, the use of conventional treatments for this disease generates significant damage to the liver and kidney functions of patients, which is why treatments are required that allow early diagnosis and selectivity for Pathogenic bacteria. In this work, a drug currently used for the treatment of tuberculosis (rifampicin) and silver nanoparticles as luminescent biomarkers are being encapsulated, and estimated by means of UV–VIS, FTIR, and DLS techniques for the design of theragnostic liposomes. The results show that this type of liposomes have important characteristics to be used as elements of early diagnosis in addition to its possible therapeutic use. Graphical abstract: [Figure not available: see fulltext.]",

author = "Rebeca Jim{\'e}nez-Rodr{\'i}guez and Janna Douda and Mota-D{\'i}az, {I. I.} and Julieta Luna-Herrera and Romera-Ibarra, {I. C.} and Casas-Esp{\'i}nola, {J. L.}",

note = "Publisher Copyright: {\textcopyright} 2023, The Author(s), under exclusive licence to The Materials Research Society.",

year = "2023",

month = apr,

doi = "10.1557/s43580-023-00496-3",

language = "Ingl{\'e}s",

volume = "8",

pages = "67--70",

journal = "MRS Advances",

issn = "2059-8521",

publisher = "Materials Research Society",

number = "3",

}

TY - JOUR

T1 - Theragnostic liposomes for the diagnosis and treatment of tuberculosis

AU - Jiménez-Rodríguez, Rebeca

AU - Douda, Janna

AU - Mota-Díaz, I. I.

AU - Luna-Herrera, Julieta

AU - Romera-Ibarra, I. C.

AU - Casas-Espínola, J. L.

PY - 2023/4

Y1 - 2023/4

N2 - The indiscriminate use of antibiotics has generated super bacteria resistant to many conventional drugs. Tuberculosis is caused by the bacterium Mycobacterium tuberculosis, the use of conventional treatments for this disease generates significant damage to the liver and kidney functions of patients, which is why treatments are required that allow early diagnosis and selectivity for Pathogenic bacteria. In this work, a drug currently used for the treatment of tuberculosis (rifampicin) and silver nanoparticles as luminescent biomarkers are being encapsulated, and estimated by means of UV–VIS, FTIR, and DLS techniques for the design of theragnostic liposomes. The results show that this type of liposomes have important characteristics to be used as elements of early diagnosis in addition to its possible therapeutic use. Graphical abstract: [Figure not available: see fulltext.]

AB - The indiscriminate use of antibiotics has generated super bacteria resistant to many conventional drugs. Tuberculosis is caused by the bacterium Mycobacterium tuberculosis, the use of conventional treatments for this disease generates significant damage to the liver and kidney functions of patients, which is why treatments are required that allow early diagnosis and selectivity for Pathogenic bacteria. In this work, a drug currently used for the treatment of tuberculosis (rifampicin) and silver nanoparticles as luminescent biomarkers are being encapsulated, and estimated by means of UV–VIS, FTIR, and DLS techniques for the design of theragnostic liposomes. The results show that this type of liposomes have important characteristics to be used as elements of early diagnosis in addition to its possible therapeutic use. Graphical abstract: [Figure not available: see fulltext.]

UR - http://www.scopus.com/inward/record.url?scp=85146387141&partnerID=8YFLogxK

U2 - 10.1557/s43580-023-00496-3

DO - 10.1557/s43580-023-00496-3

M3 - Artículo

AN - SCOPUS:85146387141

SN - 2059-8521

VL - 8

SP - 67

EP - 70

JO - MRS Advances

JF - MRS Advances

IS - 3

ER -

Theragnostic liposomes for the diagnosis and treatment of tuberculosis

Resumen

ODS de las Naciones Unidas

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto